Safety of Diabetes Medicine

In February of 2008 nhlbi announced that the action to control the risk of cardiovascular disease, diabetes mellitus (agreement) study will be stopped, because of the increased risk of death in patients with glucose-lowering therapy. 10,251 cases of type 2 diabetic patients who are undergoing medical treatment, and achieved a series of drug control blood sugar, divided into intensive silvers and blood glucose lowering standards groups.

257 people died in the intensive group therapy in order to reduce glycated hemoglobin (a marker of elevated blood glucose level), compared to less than 6%, 203 people were killed in the standard treatment group (glycosylated hemoglobin 7-7.9%). Death, including sudden death and the reasons for the cardiovascular system. Response from medical experts, including "surprise" and "shock" However, this should not have to have any surprising, because the facts glitazone drugs for diabetes, which Avandia (rosiglitazone), and Actos (pioglitazone ), the risk of cardiovascular disease is used to be called. For example, last year an article in the New England Journal of Medicine showed that the Avandia (rosiglitazone) to increase the risk of heart attack by 43%. These drugs will also liquid retention, increased the risk of heart failure. For example, in the diabetes trial results Series (taken), 4,360 cases with poorly controlled type 2 diabetic patients were randomly assigned to four years of treatment with rosiglitazone, metformin or glibenclamide. Rosiglitazone caused heart failure than glibenclamide, and with more weight (4.8 kg - converted into pounds, 5 -2.9 kg metformin), and to establish or edema fluid (may be caused by heart failure). Rosiglitazone 22 cases of heart failure, compared to 19 and 9 and metformin glibenclamide.

In the prospective pioglitazone clinical trials, in the event (positive) study, 5,238 cases of type 2 diabetes and evidence of vascular disease were randomly divided into treatment, pioglitazone or placebo to take with the typical treatment programme. There was no significant difference in the primary outcome of any vascular events; 281 pioglitazone patients developed heart failure compared with 198 pairs of placebo, 42% of the increase was highly statistically significant. Most people do not know that glitazones cause weight gain and actually create new fat cells, which allows you to more "unsaturated fatty acids, 'So, in other words, they are in the promotion of this matter, resulting in the majority of type 2 diabetes mellitus ( that is, weight gain), and the cause of this incident, we are trying to prevent the treatment of diabetic (ie, heart attack and congestive heart failure). is not a very good agreement.

Overall old diabetic drug, glibenclamide may be relatively safe, the newer drugs and cost much less. Diet and exercise is always the best prevention of the development of type 2 diabetes.